Rifamail 450 Capsule contains Rifampicin 450mg, a first-line anti-tuberculosis agent widely used for the treatment of TB and other bacterial infections. It plays a key role in combination therapy for effective TB management.
Rifampicin works by inhibiting bacterial RNA polymerase, stopping protein synthesis and promoting rapid bacterial clearance. Its efficacy in multi-drug TB regimens ensures optimal clinical outcomes.
Capsule formulation provides precise dosing, stable bioavailability, and easy administration, improving patient adherence. Due to its essential role in TB care, Rifamail 450 Capsule is in high demand across hospitals, clinics, and national TB programs.
Adding Rifamail 450 Capsule to your anti-tuberculosis and anti-infective portfolio strengthens your range with a trusted, high-rotation product. Its prescriber confidence, institutional use, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.